脑心通胶囊辅助治疗对颅内动脉粥样硬化性狭窄患者血小板膜糖蛋白及血小板参数的影响

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (730 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the effect of naoxintong capsule add-on therapy on platelet membrane glycoprotein and parameters in patients with intracranial atherosclerotic stenosis. Methods: One hundred and twenty-two patients with intracranial atherosclerotic stenosis were randomly divided into 2 groups: naoxintong capsule(n=64) and conventional western medicine(n=58). The conventional western medicine aspirin and lipitor were given to the two groups, while naoxintong capsule was additionally given to the former group. The therapeutic course for all were 6 months. The expression of platelet membrane glycoprotein PAC-1 and CD62P, platelet count(PLT), mean platelet volume(MPV), platelet distribution width(PDW) and platelet large cell ratio(P-LCR) were detected in 2 groups before and after treatment. Results: Compared with before treatment, the expression of platelet membrane glycoprotein PAC-1 and CD62P, MPV, PDW and P-LCR were significantly lower, the PLT count were significantly higher in both two groups. The differences of platelet membrane glycoprotein expression and parameters after naoxintong capsule add on therapy were more significant than conventional western therapy only. Conclusion: Naoxintong capsule add-on therapy could further inhibit the activation and aggregation of platelet, assist conventional western therapy in postponing the development of intracranial atherosclerotic stenosis.

Received: 26 October 2012

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2013/V23/I1/65

[1] Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis［J］. Circulation, 2006,113(4): 555-563.

［2］ Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association／American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline［J］. Stroke, 2006, 37(2): 577-617.

［3］高山,黄家星,黄一宁,等. 颅内大动脉狭窄的检查方法和流行病学调查［J］. 中国医学科学院学报, 2003, 25(1): 96-100.

［4］ Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis［J］. J Clin Invest, 2005, 115(12):3378-3384.

［5］ Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein Ⅱb／Ⅲa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor［J］. Mol Pharmacol, 2006, 70(4):1380-1389.

［6］ Danielyan K, Ding BS, Gottstein C, et al. Delivery of anti-platelet-endothelial cell adhesion molecule singlechain variable fragmenturokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema［J］.J Pharmacol Exp Ther, 2007, 321(3): 947-952.

［7］ Lindemann S, Krmer B, Seizer P, et al. Platelets, inflammation and atherosclerosis［J］. J Thromb Haemost, 2007, 5（suppl 1）: 203-211.

［8］ Langer HF, Bigalke B, Seizer P, et al. Interaction of platelets and inflammatory endothelium in the development and progression of coronary artery disease［J］. Semin Thromb Hemost, 2010, 36(2):131-138.

［9］ Ay C, Jungbauer LV, Kaider A, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism［J］. Thromb Haemost, 2008, 99(5):899-904.

［10］ SiegelAxel D, Daub K, Seizer P, et al. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis［J］. Cardiovasc Res, 2008, 78(1):8-17.

［11］ Marwali MR, Hu CP, Mohandas B, et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of letin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and insideout integrin signaling［J］. J Pharmacol Exp Ther, 2007, 322(3): 1324-1332.

［12］ Benner JS, Pollack MF, Smith TW,et al. Association between short-term effectiveness of statins and long term adherence to lipid-lowering therapy［J］. Am J Health Syst Pharm, 2005, 62(14):1468-1475.

［13］ Puccetti L, Sawamura T, Pasgui AL, et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients［J］. Eur J Clin Invest, 2005, 35(1): 47-51.